Safety of rituximab in a patient with chronic renal failure and low-grade non-Hodgkin lymphoma

Ralph Chebib; Claude Ghorra; Joseph Kattan

首页> 外文期刊>Journal of Cancer Research and Therapeutics >Safety of rituximab in a patient with chronic renal failure and low-grade non-Hodgkin lymphoma

【24h】

Safety of rituximab in a patient with chronic renal failure and low-grade non-Hodgkin lymphoma

机译：利妥昔单抗在慢性肾功能衰竭和低度非霍奇金淋巴瘤患者中的安全性

获取原文

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

An 82-year-old man, with known chronic renal failure and a creatinine clearance (CrCl) of 18 mL/min, was diagnosed with low-grade marginal zone non-Hodgkinlymphoma (NHL) of his right orbit. He received rituximab as single treatment (375 mg/m 2 every 3 weeks). After eight cycles, almost complete response was obtained, rituximab was extremely well-tolerated, and his creatinine levels remained stable throughout the whole treatment.

机译：一名82岁男子，患有已知的慢性肾功能衰竭，肌酐清除率（CrCl）为18 mL / min，被诊断出其右眼的低度边缘区非霍奇金淋巴瘤（NHL）。他接受了利妥昔单抗单次治疗（每3周375 mg / m 2 ）。在八个周期后，获得了几乎完全的反应，利妥昔单抗耐受性极好，并且在整个治疗过程中他的肌酐水平保持稳定。

著录项

来源
《Journal of Cancer Research and Therapeutics》 |2015年第3期|共1页
作者
Ralph Chebib; Claude Ghorra; Joseph Kattan;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation. [J] . Kaya H, Keung YK, Case D, Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation . 2002,第10期

机译：单克隆抗CD20抗体（rituximab）在大剂量化疗和自体造血细胞移植后治疗复发性低度非霍奇金淋巴瘤患者中的有效性和安全性。
2. Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era. [J] . Naokuni Uike, Ilseung Choi, Mariko Tsuda, International journal of hematology . 2014,第4期

机译：与复发或难治性低度B细胞非霍奇金淋巴瘤患者90Y-ibritumomab tiuxetan疗效相关的因素：利妥昔单抗时代94名日本患者的单中心治疗经历。
3. Factors associated with effects of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory low-grade B cell non-Hodgkin lymphoma: single-institution experience with 94 Japanese patients in rituximab era. [J] . Naokuni Uike, Ilseung Choi, Mariko Tsuda, International journal of hematology . 2014,第4期

机译：与90年 - 伊布拉特甘草患者在复发或难治性低级B细胞非霍奇金淋巴瘤患者中有关的因素：单制度经验，患有94名日本人患者。
4. Study of Multi-b-Value Diffusion-Weighted Imaging at 3.0 T for Measuring Renal Function of Patients with Chronic Renal Failure [C] . Junlai xue, Mengchao zhang, Maohua zhang International Conference on Applied Sciences, Engineering and Technology . 2014

机译：3.0T多B值扩散加权成像测量慢性肾功能衰竭患者肾功能的研究
5. Safety and Efficacy of the Immunomodulatory Drug (IMiD) Lenalidomide in Patients with Lymphoma: Development of RU051417I - Phase I/II Open-Label Study of R-ICE (Rituximab-Ifosfamide-Carboplatin-Etoposide) with Lenalidomide [R2-ICE] in Patients with First-Relapse/Primary Refractory Diffuse Large B-Cell Lymphoma (DLBCL). [D] . Kasi, Pashtoon Murtaza. 2018

机译：免疫调节药物来那度胺在淋巴瘤患者中的安全性和有效性：RU051417I-R-ICE（利妥昔单抗-异环磷酰胺-卡铂-依托泊苷）与来那度胺[R2-ICE]的I / II期开放标签研究的进展初次复发/原发性难治性弥漫性大B细胞淋巴瘤（DLBCL）。
6. Efficacy and safety of biosimilar rituximab (ZytuxTM) in newly diagnosed patients with non-Hodgkin lymphoma and chronic lymphocytic leukemia [O] . Alaa Fadhil Alwan, Manal Ali Abdulsahib, Duaa Dhahir Abbas, 2020

机译：生物仿生毒液（ZyTuxtm）在新诊断患有非霍奇金淋巴瘤和慢性淋巴细胞白血病患者中的疗效和安全性
7. Efficacy and safety of monoclonal anti-CD20 antibody (rituximab) for the treatment of patients with recurrent low-grade non-Hodgkin's lymphoma after high-dose chemotherapy and autologous hematopoietic cell transplantation [O] . Kaya Hakan, Keung Yi-Kong, Case Douglas, 2002

机译：单克隆抗CD20抗体（rituximab）治疗大剂量化学疗法和自体造血细胞移植后复发性低度非霍奇金淋巴瘤的疗效和安全性

Safety of rituximab in a patient with chronic renal failure and low-grade non-Hodgkin lymphoma

摘要

著录项

相似文献

相关主题

期刊订阅